AZP-531 is a stabilized analog of unacylated ghrelin (UAG) and functions as a selective UAG mimetic with potential therapeutic effects in metabolic disorders. It has shown beneficial effects in clinical and preclinical models by modulating glucose metabolism, insulin sensitivity, and fat accumulation without stimulating appetite or promoting weight gain, which differentiates it from acylated ghrelin. In a Phase 2 clinical trial involving patients with Prader-Willi syndrome, AZP-531 treatment for 2 weeks led to a significant reduction in hyperphagia scores compared to placebo (−4.3 vs. −0.3, P<0.05), with a favorable safety profile. Additionally, in type 2 diabetes patients, AZP-531 significantly improved postprandial glucose levels (−24 mg/dL vs. placebo, P=0.02) after a 14-day treatment period. These data support its potential use in metabolic and appetite-related disorders.
MedKoo Cat#: 529208
Name: AZP-531
CAS#: 1088543-62-7
Chemical Formula: C40H63N15O13
Exact Mass: 961.4730
Molecular Weight: 962.03
Elemental Analysis: C, 49.94; H, 6.60; N, 21.84; O, 21.62
The following data is based on the product molecular weight 962.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
